DuraHeart<sup>TM</sup> Magnetically Levitated Left Ventricular Assist Device
-
- Sakaguchi Taichi
- Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine
-
- Matsumiya Goro
- Department of Cardiovascular Surgery, Chiba University Graduate School of Medicine
-
- Yoshioka Daisuke
- Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine
-
- Miyagawa Shigeru
- Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine
-
- Nishi Hiroyuki
- Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine
-
- Yoshikawa Yasushi
- Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine
-
- Fukushima Satsuki
- Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine
-
- Saito Shunsuke
- Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine
-
- Ueno Takayoshi
- Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine
-
- Sawa Yoshiki
- Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine
書誌事項
- タイトル別名
-
- – Osaka University Experience –
この論文をさがす
説明
Background: The DuraHeart left ventricular assist device (LVAD) is the world’s first approved magnetically levitated implantable centrifugal pump. We report our initial experience with the DuraHeart as a bridge to heart transplantation. Methods and Results: Between 2008 and 2011, 23 patients (17 males; mean age 35 years, range 16–53 years) with endstage heart failure underwent implantation with the DuraHeart LVAD at Osaka University Hospital. Of those, 7 underwent conversion surgery from a Nipro paracorporeal LVAD to the DuraHeart. There were no deaths during the mean support period of 559±241 days (176–999 days). In total, 17 patients (74%) remain with the LVAD and 5 (22%) underwent heart transplantation after 580±302 days (176–982 days) of support. Major adverse events included 8 (34%) driveline/pocket infections, 4 (17%) cerebrovascular accidents, 4 (17%) right heart failures requiring mechanical support, and 3 (13%) mechanical device failures (magnetic levitation failure caused by driveline fracture). Of the 5 patients who developed pump pocket infection, 3 underwent previous conversion surgery from the Nipro LVAD. Conclusions: Our initial experience with the DuraHeart LVAD in Japan demonstrated excellent long-term survival with acceptable rates of adverse events. With refinement of the system, including mechanical durability, this pump will further enhance the quality of life for patients who require long-term mechanical circulatory support. (Circ J 2013; 77: 1736–1741)<br>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 77 (7), 1736-1741, 2013
一般社団法人 日本循環器学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001205103422976
-
- NII論文ID
- 10031173754
-
- NII書誌ID
- AA11591968
-
- COI
- 1:STN:280:DC%2BC3srmtVOhtQ%3D%3D
-
- ISSN
- 13474820
- 13469843
-
- PubMed
- 23595087
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可